Towa Pharmaceutical Co., Ltd.
4553.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | ¥131,874 | ¥139,295 | ¥93,275 | ¥135,245 |
| - Cash | ¥45,471 | ¥29,650 | ¥24,257 | ¥32,830 |
| + Debt | ¥232,366 | ¥202,356 | ¥173,065 | ¥144,128 |
| Enterprise Value | ¥318,769 | ¥312,001 | ¥242,083 | ¥246,543 |
| Revenue | ¥259,594 | ¥227,934 | ¥208,859 | ¥165,615 |
| % Growth | 13.9% | 9.1% | 26.1% | – |
| Gross Profit | ¥94,729 | ¥81,383 | ¥72,714 | ¥70,186 |
| % Margin | 36.5% | 35.7% | 34.8% | 42.4% |
| EBITDA | ¥48,055 | ¥35,536 | ¥25,143 | ¥29,492 |
| % Margin | 18.5% | 15.6% | 12% | 17.8% |
| Net Income | ¥18,986 | ¥16,173 | ¥2,201 | ¥15,914 |
| % Margin | 7.3% | 7.1% | 1.1% | 9.6% |
| EPS Diluted | 385.7 | 328.58 | 44.72 | 316.19 |
| % Growth | 17.4% | 634.7% | -85.9% | – |
| Operating Cash Flow | ¥23,401 | ¥8,212 | ¥2,544 | ¥22,129 |
| Capital Expenditures | -¥28,736 | -¥39,325 | -¥30,469 | -¥13,576 |
| Free Cash Flow | -¥5,335 | -¥31,113 | -¥27,925 | ¥8,553 |